DALLAS, Feb. 21 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. announced today that it will conduct a conference call to discuss its proposed acquisition of Somanta Pharmaceuticals with the investment community. The call will take place on Thursday, February 22, 2007, after the financial markets close at 4:00 pm EST. Mr. Stephen R. Seiler, President and CEO of Access and Dr. Agamemnon Epenetos, CEO of Somanta will co-host the call.
Interested parties may participate in the call by dialing (877) 407-8293; international callers dial (201) 689-8349 about 5-10 minutes prior to 4:00 pm EST. The conference call will also be available on replay starting at 7:00 pm EST on February 22, 2007, and ending on March 22, 2007. For the replay, please dial (877) 660-6853 (replay account # 294, replay conference # 232644). The access number for the replay for international callers is (201) 612-7415 (replay account # 294, replay conference # 232644).
About Access Pharmaceuticals, Inc.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing and commercializing propriety products for the treatment and supportive care of cancer patients. Access’ products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis for which marketing allowance has been granted by the FDA. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.
Access Pharmaceuticals, Inc.
CONTACT: Stephen B. Thompson, Vice President, Chief Financial Officer ofAccess Pharmaceuticals, Inc., +1-214-905-5100; or investor relations,Donald C. Weinberger, or media, Alisa Steinberg, both of Wolfe AxelrodWeinberger Assoc. LLC, +1-212-370-4500; or Andrew Hellman of CEOcast, Inc.,+1-212-732-4300, all for Access Pharmaceuticals, Inc.
